Anika Appoints Mira Leiwant as Vice President of Regulatory Affairs, Quality, and Clinical Affairs
October 14, 2019
BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated company, focused on developing regenerative therapies leveraging its proprietary hyaluronic acid (“HA”) technology platform to provide treatments across the joint preservation and restoration continuum of care, today announced the appointment of Mira Leiwant to the newly created position of Vice President of Regulatory Affairs, Quality and Clinical Affairs. Ms. Leiwant joins the company with over 20 years of experience leading the regulatory, quality, and clinical affairs strategies for companies specializing in developing, manufacturing, and commercializing medical devices and pharmaceutical products. In this role, Ms. Leiwant will oversee Anika’s global regulatory and clinical strategy, regulatory submissions, interactions with U.S. and international governmental health authorities, and quality and clinical affairs teams and processes.
“We are pleased to strengthen the executive management team’s regulatory, quality, and clinical expertise with the addition of Ms. Leiwant,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “Her deep experience in developing and implementing U.S. and international regulatory strategies will be invaluable as we advance our joint preservation and restoration pipeline to expand our portfolio of new products in the market to achieve our growth objectives.”
“Anika has an expansive pipeline of differentiated regenerative therapies, and I am delighted to join its leadership team at this transformative time for the Company,” said Mira Leiwant, Vice President of Regulatory Affairs, Quality, and Clinical Affairs at Anika Therapeutics. “I look forward to developing Anika’s global regulatory and clinical strategies, as well as enhancing its quality assurance processes to efficiently bring Anika’s innovative solutions to patients around the world.”
Prior to joining Anika, Ms. Leiwant spent three years at BTG International, an international specialist healthcare company, as Vice President, Regulatory Affairs. Before joining BTG International, Ms. Leiwant served as Senior Director, Regulatory Affairs and Quality Engineering for LifeCell Corporation, a medical device subsidiary of Allergan. Previously, Ms. Leiwant held leadership positions in Quality Assurance at Svelte Medical Systems, Inc. and Vascular Therapies. Ms. Leiwant obtained both M.E. and B.S. in Mechanical Engineering with Bioengineering option from Cornell University.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc.(NASDAQ: ANIK) is a global, integrated regenerative therapies company based in Bedford, Massachusetts. Anika is committed to delivering therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The Company has over two decades of global expertise commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology platform. For more information about Anika, please visit www.anikatherapeutics.com.
Contacts
For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
For Media Inquiries:
W2O Group
Sonal Vasudev, 917-523-1418,
sonal@w2ogroup.com
